These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 34882081)

  • 1. Heart failure with preserved left ventricular ejection fraction in patients with obstructive sleep apnea syndrome: prognostic value of biomarkers.
    Grakova EV; Yakovlev AV; Shilov SN; Berezikova EN; Kopeva KV; Yakovleva NF; Ogurkova ON; Teplyakov AT
    Kardiologiia; 2021 Nov; 61(11):77-88. PubMed ID: 34882081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of sST2 and NT-proBNP at admission in heart failure with preserved, mid-ranged and reduced ejection fraction.
    Huang A; Qi X; Hou W; Qi Y; Zhao N; Liu K
    Acta Cardiol; 2018 Feb; 73(1):41-48. PubMed ID: 28944719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Diagnostic value of combining serum soluble ST2 and interleukin-33 for heart failure patients with preserved left ventricular ejection fraction].
    Luo NS; Zhang HF; Liu PM; Lin YQ; Huang TC; Yang Y; Wang JF
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Mar; 45(3):198-203. PubMed ID: 28316175
    [No Abstract]   [Full Text] [Related]  

  • 4. Acute coronary syndrome in patients with cancer: features of the course and the possibility of predicting hospital and long-term (6 months) periods using GDF-15, NT-proBNP, hs-CRP biomarkers.
    Shalenkova MA; Ivanov AV; Klimkin PF
    Kardiologiia; 2021 Oct; 61(10):4-13. PubMed ID: 34763634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating levels and prognostic value of soluble ST2 in heart failure are less influenced by age than N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T.
    Aimo A; Januzzi JL; Vergaro G; Richards AM; Lam CSP; Latini R; Anand IS; Cohn JN; Ueland T; Gullestad L; Aukrust P; Brunner-La Rocca HP; Bayes-Genis A; Lupón J; de Boer RA; Takeishi Y; Egstrup M; Gustafsson I; Gaggin HK; Eggers KM; Huber K; Gamble GD; Ling LH; Leong KTG; Yeo PSD; Ong HY; Jaufeerally F; Ng TP; Troughton R; Doughty RN; Passino C; Emdin M
    Eur J Heart Fail; 2020 Nov; 22(11):2078-2088. PubMed ID: 31919929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Not Available].
    Protasov VN; Narusov OY; Skvortsov AA; Protasova DE; Kuznetsova TV; Petrukhina AA; Masenko VP; Tereshchenko SN
    Kardiologiia; 2019 Jan; 59(1S):53-64. PubMed ID: 30706839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association Between Angiotensin Receptor-Neprilysin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction.
    Murphy SP; Prescott MF; Maisel AS; Butler J; Piña IL; Felker GM; Ward JH; Williamson KM; Camacho A; Kandanelly RR; Solomon SD; Januzzi JL
    Circ Heart Fail; 2021 Jun; 14(6):e008410. PubMed ID: 33998243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined use of high-sensitivity ST2 and NT-proBNP for predicting major adverse cardiovascular events in coronary heart failure.
    Bai J; Han L; Liu H
    Ann Palliat Med; 2020 Jul; 9(4):1976-1989. PubMed ID: 32762223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effectiveness of Outpatient Treatment Under the Control of the Soluble ST2 Receptor Concentration in Patients With Heart Failure With Reduced Ejection Fraction After Acute Decompensation of Heart Failure.
    Muksinova MD; Narusov OY; Sychev AV; Sharf TV; Masenko VP; Tereshchenko SN; Skvortsov AA
    Kardiologiia; 2023 Dec; 63(12):87-92. PubMed ID: 38156496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Diagnostic Value of Biochemical Markers in Patients With Chronic Heart Failure With Reduced, Borderline and Preserved Left Ventricular Ejection Fraction].
    Bazaeva EV; Myasnikov RP; Metelskaya VA; Boytsov SA
    Kardiologiia; 2017 Mar; 57(3):39-45. PubMed ID: 28762934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Soluble Suppression of Tumorogenicity 2 Increases Opportunities for Risk Stratification After Acute Heart Failure Decompensation].
    Skvortsov AA; Protasov VN; Narusov OY; Koshkina DE; Nasonova SN; Masenko VP; Tereschenko SN
    Kardiologiia; 2017 Jan; (1):48-58. PubMed ID: 28290833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic utility of ST2 in patients with acute dyspnea and preserved left ventricular ejection fraction.
    Shah KB; Kop WJ; Christenson RH; Diercks DB; Henderson S; Hanson K; Li SY; deFilippi CR
    Clin Chem; 2011 Jun; 57(6):874-82. PubMed ID: 21515743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. sST2 Predicts Outcome in Chronic Heart Failure Beyond NT-proBNP and High-Sensitivity Troponin T.
    Emdin M; Aimo A; Vergaro G; Bayes-Genis A; Lupón J; Latini R; Meessen J; Anand IS; Cohn JN; Gravning J; Gullestad L; Broch K; Ueland T; Nymo SH; Brunner-La Rocca HP; de Boer RA; Gaggin HK; Ripoli A; Passino C; Januzzi JL
    J Am Coll Cardiol; 2018 Nov; 72(19):2309-2320. PubMed ID: 30384887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction.
    Manzano-Fernández S; Mueller T; Pascual-Figal D; Truong QA; Januzzi JL
    Am J Cardiol; 2011 Jan; 107(2):259-67. PubMed ID: 21211603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure.
    Pascual-Figal DA; Manzano-Fernández S; Boronat M; Casas T; Garrido IP; Bonaque JC; Pastor-Perez F; Valdés M; Januzzi JL
    Eur J Heart Fail; 2011 Jul; 13(7):718-25. PubMed ID: 21551163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis of chronic heart failure by the soluble suppression of tumorigenicity 2 and N-terminal pro-brain natriuretic peptide.
    Jin XL; Huang N; Shang H; Zhou MC; Hong Y; Cai WZ; Huang J
    J Clin Lab Anal; 2018 Mar; 32(3):. PubMed ID: 28719009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Diagnostic value of plasma concentration of pro-brain natriuretic peptide in congestive heart failure in pediatric patients with ventricular septal defects].
    Wu YR; Chen SB; Huang MR; Zhang YQ; Sun K; Chen S
    Zhonghua Er Ke Za Zhi; 2005 Mar; 43(3):161-4. PubMed ID: 15833183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pro-brain natriuretic peptide plasma levels, left ventricular dimensions and ejection fraction in acute dyspnoea.
    Shaikh K; Hanif B; Siddique AA; Shaikh MY; Khan MN
    J Coll Physicians Surg Pak; 2012 Dec; 22(12):751-5. PubMed ID: 23217478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble ST2 protein in the short-term prognosis after hospitalisation in chronic systolic heart failure.
    Wojtczak-Soska K; Sakowicz A; Pietrucha T; Lelonek M
    Kardiol Pol; 2014; 72(8):725-34. PubMed ID: 24846354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Value of N-terminal pro-brain natriuretic peptide in evaluating early septic cardiac dysfunction in neonates].
    Yang C; Liu F; Han M; Li B; Shen Q; Xu P; Yang Q
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2020 Jun; 32(6):711-715. PubMed ID: 32684218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.